Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans reveal how common drugs may dull smoking urges

NCT ID NCT05587361

Knowledge-focused Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the drug propranolol and nicotine patches, alone or together, change brain activity and cravings when smokers see smoking-related cues. Eighty daily smokers will undergo brain scans while viewing these cues. The goal is to understand the brain mechanisms behind smoking urges, not to help participants quit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Propranolol and nicotine patch
What this could lead to
If successful, this could reveal how these medications change brain activity related to smoking urges, potentially guiding future treatments for nicotine dependence.
What could go wrong
This is an early-stage experimental study with only 80 participants, not designed to test a treatment. Results may not translate to real-world smoking cessation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Generally healthy 2. Age 21-60 3. Right-handed using a three-item scale 4. Daily smoker of ≥ 5 cigarettes/day delivering 0.5 mg nicotine (FTC) 5. Smoking regularly for ≥ 1 year, with stable smoking for the past 6 months 6. Afternoon expired Carbon Monoxide (CO) concentration ≥ 6 ppm and/or morning urinary cotinine \>100 ng/ml 7. Must identity at least 4 different smoking locations used in a typical week 8. Able to read and understand English Exclusion Criteria: 1. Inability to attend all required sessions 2. Significant health problems that would preclude active participation 3. Presence of conditions that would make MRI unsafe (e.g. pacemaker) or (e.g. weight and body shape) 4. Current use of psychoactive medications/drugs as indicated by self-report or urine screen 5. Positive breath alcohol concentration 6. Pregnant, breastfeeding, or planning to become pregnant during the course of the study (females) 7. Problems with vision that cannot be corrected with contacts or glasses 8. Current regular use of smokeless tobacco, smoking cessation medications, or other nicotine containing products (e.g. electronic cigarettes) 9. Current use of beta-adrenergic medications (e.g. beta-blockers) or other blood pressure medications 10. Systolic blood pressure \< 90 mmHg or diastolic blood pressure \< 60 mmHg (sitting or standing) 11. Abnormal EKG 12. Presence of severe anemia 13. Presence of electrolyte imbalance that could impact blood pressure 14. Presence of any other contraindications for propranolol or nicotine patch (e.g. cardiovascular disease, bronchial asthma, prior allergic reactions, diabetes)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cigarette smoking are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cigarette Smoking nicotine dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cigarette smoking Nicotine dependence Tobacco use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hardesty Center for Clinical Research and Neuroscience

    RECRUITING

    Tulsa, Oklahoma, 74136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.